Gannex Announces Poster Presentation of Positive Interim 12-Week Results from Phase II Clinical Trial of ASC41 in Patients with Biopsy-Confirmed MASH at EASL CONGRESS 2024 ...Middle East

--Up to 68.2% mean relative reduction in liver fat content from baseline among biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients receiving 12-week treatment of ASC41 --Significant and clinically meaningful reductions in liver fat, alanine aminotransferase...

Hence then, the article about gannex announces poster presentation of positive interim 12 week results from phase ii clinical trial of asc41 in patients with biopsy confirmed mash at easl congress 2024 was published today ( Tuesday 11/06/2024 - 03:21 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Gannex Announces Poster Presentation of Positive Interim 12-Week Results from Phase II Clinical Trial of ASC41 in Patients with Biopsy-Confirmed MASH at EASL CONGRESS 2024 )

Also on site :

• Dunkin’s Limited-Edition Tumbler Is Already in High Demand—How to Get Yours
• A Shocking Recoupling! And the Second Vote Opens! Who Are the New Couples of ‘Love Island USA’ 2026
• Did 'Summer House: The Aftermath' Just Hard Launch Amanda Batula's Redemption Arc? Some Fans Say 'Too Late'